SEARCH

SEARCH BY CITATION

References

  • 1
    Stacker SA,Achen MG,Jussila L,Baldwin ME,Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 57383.
  • 2
    Cueni LN,Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol 2006; 126: 216777.
  • 3
    Kaipainen A,Korhonen J,Mustonen T,van Hinsbergh VW,Fang GH,Dumont D,Breitman M,Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 356670.
  • 4
    Breiteneder-Geleff S,Soleiman A,Kowalski H,Horvat R,Amann G,Kriehuber E,Diem K,Weninger W,Tschachler E,Alitalo K,Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154: 38594.
  • 5
    Banerji S,Ni J,Wang SX,Clasper S,Su J,Tammi R,Jones M,Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789801.
  • 6
    Wigle JT,Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 76978.
  • 7
    Makinen T,Veikkola T,Mustjoki S,Karpanen T,Catimel B,Nice EC,Wise L,Mercer A,Kowalski H,Kerjaschki D,Stacker SA,Achen MG, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001; 20: 476273.
  • 8
    Partanen TA,Arola J,Saaristo A,Jussila L,Ora A,Miettinen M,Stacker SA,Achen MG,Alitalo K. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000; 14: 208796.
  • 9
    Witmer AN,van Blijswijk BC,Dai J,Hofman P,Partanen TA,Vrensen GF,Schlingemann RO. VEGFR-3 in adult angiogenesis. J Pathol 2001; 195: 4907.
  • 10
    Valtola R,Salven P,Heikkila P,Taipale J,Joensuu H,Rehn M,Pihlajaniemi T,Weich H,deWaal R,Alitalo K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154: 138190.
  • 11
    Partanen TA,Alitalo K,Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86: 240612.
  • 12
    Kubo H,Fujiwara T,Jussila L,Hashi H,Ogawa M,Shimizu K,Awane M,Sakai Y,Takabayashi A,Alitalo K,Yamaoka Y,Nishikawa SI. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000; 96: 54653.
  • 13
    Evangelou E,Kyzas PA,Trikalinos TA. Comparison of the diagnostic accuracy of lymphatic endothelium markers: bayesian approach. Mod Pathol 2005; 18: 14907.
  • 14
    Schacht V,Ramirez MI,Hong YK,Hirakawa S,Feng D,Harvey N,Williams M,Dvorak AM,Dvorak HF,Oliver G,Detmar M. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003; 22: 354656.
  • 15
    Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 2004; 112: 52638.
  • 16
    Mouta Carreira C,Nasser SM,di Tomaso E,Padera TP,Boucher Y,Tomarev SI,Jain RK. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001; 61: 807984.
  • 17
    Petrova TV,Makinen T,Makela TP,Saarela J,Virtanen I,Ferrell RE,Finegold DN,Kerjaschki D,Yla-Herttuala S,Alitalo K. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002; 21: 45939.
  • 18
    Parr C,Jiang WG. Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int J Oncol 2003; 23: 5339.
  • 19
    Petrova TV,Karpanen T,Norrmen C,Mellor R,Tamakoshi T,Finegold D,Ferrell R,Kerjaschki D,Mortimer P,Yla-Herttuala S,Miura N,Alitalo K. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004; 10: 97481.
  • 20
    Tammela T,Petrova TV,Alitalo K. Molecular lymphangiogenesis: new players. Trends Cell Biol 2005; 15: 43441.
  • 21
    Makinen T,Adams RH,Bailey J,Lu Q,Ziemiecki A,Alitalo K,Klein R,Wilkinson GA. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 2005; 19: 397410.
  • 22
    Fenoglio CM,Kaye GI,Lane N. Distribution of human colonic lymphatics in normal, hyperplastic, and adenomatous tissue. Its relationship to metastasis from small carcinomas in pedunculated adenomas, with two case reports. Gastroenterology 1973; 64: 5166.
  • 23
    Jeltsch M,Kaipainen A,Joukov V,Meng X,Lakso M,Rauvala H,Swartz M,Fukumura D,Jain RK,Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 14235.
  • 24
    Tammela T,Saaristo A,Lohela M,Morisada T,Tornberg J,Norrmen C,Oike Y,Pajusola K,Thurston G,Suda T,Yla-Herttuala S,Alitalo K. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005; 105: 46428.
  • 25
    Rozen P,Young G,Levin B,Spann SJ. Colorectal cancer in clinical practice, 2nd edn. London and New York: Taylor and Francis, 2006.
  • 26
    Baddi L,Benson A,III. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist 2005; 10: 32531.
  • 27
    Markowitz SD,Dawson DM,Willis J,Willson JK. Focus on colon cancer. Cancer Cell 2002; 1: 2336.
  • 28
    Scheele J,Stang R,Altendorf-Hofmann A,Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 5971.
  • 29
    Minagawa M,Makuuchi M,Torzilli G,Takayama T,Kawasaki S,Kosuge T,Yamamoto J,Imamura H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231: 48799.
  • 30
    Skobe M,Hawighorst T,Jackson DG,Prevo R,Janes L,Velasco P,Riccardi L,Alitalo K,Claffey K,Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 1928.
  • 31
    Stacker SA,Caesar C,Baldwin ME,Thornton GE,Williams RA,Prevo R,Jackson DG,Nishikawa S,Kubo H,Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 18691.
  • 32
    Dadras SS,Paul T,Bertoncini J,Brown LF,Muzikansky A,Jackson DG,Ellwanger U,Garbe C,Mihm MC,Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162: 195160.
  • 33
    Schoppmann SF,Bayer G,Aumayr K,Taucher S,Geleff S,Rudas M,Kubista E,Hausmaninger H,Samonigg H,Gnant M,Jakesz R,Horvat R. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004; 240: 30612.
  • 34
    Kyzas PA,Geleff S,Batistatou A,Agnantis NJ,Stefanou D. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 2005; 206: 1707.
  • 35
    Maula SM,Luukkaa M,Grenman R,Jackson D,Jalkanen S,Ristamaki R. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003; 63: 19206.
  • 36
    Padera TP,Stoll BR,Tooredman JB,Capen D,di Tomaso E,Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004; 427: 695.
  • 37
    Padera TP,Kadambi A,di Tomaso E,Carreira CM,Brown EB,Boucher Y,Choi NC,Mathisen D,Wain J,Mark EJ,Munn LL,Jain RK. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296: 18836.
  • 38
    Leu AJ,Berk DA,Lymboussaki A,Alitalo K,Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60: 43247.
  • 39
    Omachi T,Kawai Y,Mizuno R,Nomiyama T,Miyagawa S,Ohhashi T,Nakayama J. Immunohistochemical demonstration of proliferating lymphatic vessels in colorectal carcinoma and its clinicopathological significance. Cancer Lett 2006; 246: 16772.
  • 40
    Liang P,Hong JW,Ubukata H,Liu HR,Watanabe Y,Katano M,Motohashi G,Kasuga T,Nakada I,Tabuchi T. Increased density and diameter of lymphatic microvessels correlate with lymph node metastasis in early stage invasive colorectal carcinoma. Virchows Arch 2006; 448: 5705.
  • 41
    Kaneko I,Tanaka S,Oka S,Kawamura T,Hiyama T,Ito M,Yoshihara M,Shimamoto F,Chayama K. Lymphatic vessel density at the site of deepest penetration as a predictor of lymph node metastasis in submucosal colorectal cancer. Dis Colon Rectum 2007; 50: 1321.
  • 42
    Shayan R,Achen MG,Stacker SA. Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis 2006; 27: 172938.
  • 43
    He Y,Rajantie I,Pajusola K,Jeltsch M,Holopainen T,Yla-Herttuala S,Harding T,Jooss K,Takahashi T,Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005; 65: 473946.
  • 44
    Alitalo K,Tammela T,Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438: 94653.
  • 45
    Saad RS,Kordunsky L,Liu YL,Denning KL,Kandil HA,Silverman JF. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 2006; 19: 131723.
  • 46
    Bertolini F,Shaked Y,Mancuso P,Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6: 83545.
  • 47
    Blann AD,Woywodt A,Bertolini F,Bull TM,Buyon JP,Clancy RM,Haubitz M,Hebbel RP,Lip GY,Mancuso P,Sampol J,Solovey A, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93: 22835.
  • 48
    Lyden D,Hattori K,Dias S,Costa C,Blaikie P,Butros L,Chadburn A,Heissig B,Marks W,Witte L,Wu Y,Hicklin D, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194201.
  • 49
    Peters BA,Diaz LA,Polyak K,Meszler L,Romans K,Guinan EC,Antin JH,Myerson D,Hamilton SR,Vogelstein B,Kinzler KW,Lengauer C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 2612.
  • 50
    Rafii S,Lyden D,Benezra R,Hattori K,Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 82635.
  • 51
    Asahara T,Murohara T,Sullivan A,Silver M,van der Zee R,Li T,Witzenbichler B,Schatteman G,Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 9647.
  • 52
    Salven P,Mustjoki S,Alitalo R,Alitalo K,Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003; 101: 16872.
  • 53
    Kerjaschki D,Huttary N,Raab I,Regele H,Bojarski-Nagy K,Bartel G,Krober SM,Greinix H,Rosenmaier A,Karlhofer F,Wick N,Mazal PR. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med 2006; 12: 2304.
  • 54
    He Y,Rajantie I,Ilmonen M,Makinen T,Karkkainen MJ,Haiko P,Salven P,Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 2004; 64: 373740.
  • 55
    Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest 2005; 115: 231619.
  • 56
    Maruyama K,Ii M,Cursiefen C,Jackson DG,Keino H,Tomita M,Van Rooijen N,Takenaka H,D'Amore PA,Stein-Streilein J,Losordo DW,Streilein JW. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 2005; 115: 236372.
  • 57
    Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 316.
  • 58
    Streubel B,Chott A,Huber D,Exner M,Jager U,Wagner O,Schwarzinger I. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 2509.
  • 59
    Mattila MM,Ruohola JK,Karpanen T,Jackson DG,Alitalo K,Harkonen PL. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 2002; 98: 94651.
  • 60
    Kazama S,Kitayama J,Watanabe T,Nagawa H. Expression pattern of vascular endothelial growth factor-C in human colorectal normal mucosa and neoplastic mucosa. Hepatogastroenterology 2004; 51: 915.
  • 61
    Onogawa S,Kitadai Y,Tanaka S,Kuwai T,Kimura S,Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004; 95: 329.
  • 62
    Kawakami M,Furuhata T,Kimura Y,Yamaguchi K,Hata F,Sasaki K,Hirata K. Quantification of vascular endothelial growth factor-C and its receptor-3 messenger RNA with real-time quantitative polymerase chain reaction as a predictor of lymph node metastasis in human colorectal cancer. Surgery 2003; 133: 3008.
  • 63
    Kawakami M,Furuhata T,Kimura Y,Yamaguchi K,Hata F,Sasaki K,Hirata K. Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J Exp Clin Cancer Res 2003; 22: 22937.
  • 64
    Jia YT,Li ZX,He YT,Liang W,Yang HC,Ma HJ. Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer. World J Gastroenterol 2004; 10: 32613.
  • 65
    Maeda K,Yashiro M,Nishihara T,Nishiguchi Y,Sawai M,Uchima K,Onoda N,Ohira M,Ishikawa T,Hirakawa K. Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum. Surg Today 2003; 33: 7369.
  • 66
    Furudoi A,Tanaka S,Haruma K,Kitadai Y,Yoshihara M,Chayama K,Shimamoto F. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 2002; 62: 15766.
  • 67
    Kawakami M,Yanai Y,Hata F,Hirata K. Vascular endothelial growth factor C promotes lymph node metastasis in a rectal cancer orthotopic model. Surg Today 2005; 35: 1318.
  • 68
    Mandriota SJ,Jussila L,Jeltsch M,Compagni A,Baetens D,Prevo R,Banerji S,Huarte J,Montesano R,Jackson DG,Orci L,Alitalo K, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 67282.
  • 69
    Hirakawa S,Brown LF,Kodama S,Paavonen K,Alitalo K,Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2006; 109: 101017.
  • 70
    Funaki H,Nishimura G,Harada S,Ninomiya I,Terada I,Fushida S,Tani T,Fujimura T,Kayahara M,Shimizu K,Ohta T,Miwa K. Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma. Oncology 2003; 64: 41622.
  • 71
    White JD,Hewett PW,Kosuge D,McCulloch T,Enholm BC,Carmichael J,Murray JC. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002; 62: 166975.
  • 72
    Von Marschall Z,Scholz A,Stacker SA,Achen MG,Jackson DG,Alves F,Schirner M,Haberey M,Thierauch KH,Wiedenmann B,Rosewicz S. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int J Oncol 2005; 27: 66979.
  • 73
    Ishigami SI,Arii S,Furutani M,Niwano M,Harada T,Mizumoto M,Mori A,Onodera H,Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 137984.
  • 74
    Cursiefen C,Chen L,Borges LP,Jackson D,Cao J,Radziejewski C,D'Amore PA,Dana MR,Wiegand SJ,Streilein JW. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 104050.
  • 75
    Bjorndahl MA,Cao R,Burton JB,Brakenhielm E,Religa P,Galter D,Wu L,Cao Y. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res 2005; 65: 92618.
  • 76
    Hirakawa S,Kodama S,Kunstfeld R,Kajiya K,Brown LF,Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201: 108999.
  • 77
    Elagoz S,Egilmez R,Koyuncu A,Muslehiddinoglu A,Arici S. The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer. Pathol Oncol Res 2006; 12: 217.
  • 78
    el-Hariry I,Pignatelli M,Lemoine N. Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours. J Pathol 1997; 181: 3945.
  • 79
    Tabara H,Kohno H,Dhar DK,Kotoh T,Yoshimura H,Masunaga R,Tachibana M,Kubota H,Nagasue N. Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients. Acta Oncol 2001; 40: 6228.
  • 80
    Chang LK,Garcia-Cardena G,Farnebo F,Fannon M,Chen EJ,Butterfield C,Moses MA,Mulligan RC,Folkman J,Kaipainen A. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA 2004; 101: 1165863.
  • 81
    Lindmark G,Sundberg C,Glimelius B,Pahlman L,Rubin K,Gerdin B. Stromal expression of platelet-derived growth factor β-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 1993; 69: 6829.
  • 82
    Cao R,Bjorndahl MA,Religa P,Clasper S,Garvin S,Galter D,Meister B,Ikomi F,Tritsaris K,Dissing S,Ohhashi T,Jackson DG, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004; 6: 33345.
  • 83
    Ahmad SA,Liu W,Jung YD,Fan F,Reinmuth N,Bucana CD,Ellis LM. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 2001; 92: 113843.
  • 84
    Morisada T,Oike Y,Yamada Y,Urano T,Akao M,Kubota Y,Maekawa H,Kimura Y,Ohmura M,Miyamoto T,Nozawa S,Koh GY, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005; 105: 464956.
  • 85
    Ochiumi T,Tanaka S,Oka S,Hiyama T,Ito M,Kitadai Y,Haruma K,Chayama K. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 2004; 24: 53947.
  • 86
    Chung YC,Hou YC,Chang CN,Hseu TH. Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 2006; 94: 6318.
  • 87
    Gale NW,Thurston G,Hackett SF,Renard R,Wang Q,McClain J,Martin C,Witte C,Witte MH,Jackson D,Suri C,Campochiaro PA, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3: 41123.
  • 88
    Otte JM,Schmitz F,Kiehne K,Stechele HU,Banasiewicz T,Krokowicz P,Nakamura T,Folsch UR,Herzig K. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000; 61: 23746.
  • 89
    Kajiya K,Hirakawa S,Ma B,Drinnenberg I,Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005; 24: 288595.
  • 90
    Bjorndahl M,Cao R,Nissen LJ,Clasper S,Johnson LA,Xue Y,Zhou Z,Jackson D,Hansen AJ,Cao Y. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 155938.
  • 91
    Barozzi C,Ravaioli M,D'Errico A,Grazi GL,Poggioli G,Cavrini G,Mazziotti A,Grigioni WF. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002; 94: 64757.
  • 92
    Joukov V,Pajusola K,Kaipainen A,Chilov D,Lahtinen I,Kukk E,Saksela O,Kalkkinen N,Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 29098.
  • 93
    Joukov V,Sorsa T,Kumar V,Jeltsch M,Claesson-Welsh L,Cao Y,Saksela O,Kalkkinen N,Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997; 16: 3898911.
  • 94
    Stacker SA,Stenvers K,Caesar C,Vitali A,Domagala T,Nice E,Roufail S,Simpson RJ,Moritz R,Karpanen T,Alitalo K,Achen MG. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 1999; 274: 3212736.
  • 95
    George ML,Tutton MG,Janssen F,Arnaout A,Abulafi AM,Eccles SA,Swift RI. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001; 3: 4207.
  • 96
    Hanrahan V,Currie MJ,Gunningham SP,Morrin HR,Scott PA,Robinson BA,Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003; 200: 18394.
  • 97
    Takeuchi H,Bilchik A,Saha S,Turner R,Wiese D,Tanaka M,Kuo C,Wang HJ,Hoon DS. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003; 9: 14808.
  • 98
    Schoppmann SF,Birner P,Stockl J,Kalt R,Ullrich R,Caucig C,Kriehuber E,Nagy K,Alitalo K,Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 94756.
  • 99
    Bikfalvi A,Klein S,Pintucci G,Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997; 18: 2645.
  • 100
    Cao R,Bjorndahl MA,Gallego MI,Chen S,Religa P,Hansen AJ,Cao Y. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006; 107: 35316.
  • 101
    Fukuura T,Miki C,Inoue T,Matsumoto K,Suzuki H. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br J Cancer 1998; 78: 4549.
  • 102
    Tsukinoki K,Yasuda M,Mori Y,Asano S,Naito H,Ota Y,Osamura RY,Watanabe Y. Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. Oncol Rep 2004; 12: 101721.
  • 103
    Kim CH,Moon SK,Bae JH,Lee JH,Han JH,Kim K,Choi EC. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2006; 126: 8894.
  • 104
    Freier S,Weiss O,Eran M,Flyvbjerg A,Dahan R,Nephesh I,Safra T,Shiloni E,Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44: 7048.
  • 105
    Akagi Y,Liu W,Zebrowski B,Xie K,Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998; 58: 400814.
  • 106
    Salameh A,Galvagni F,Bardelli M,Bussolino F,Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005; 106: 342331.
  • 107
    Rebhun RB,Langley RR,Yokoi K,Fan D,Gershenwald JE,Fidler IJ. Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 2006; 8: 74757.
  • 108
    Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 109
    Karpanen T,Egeblad M,Karkkainen MJ,Kubo H,Yla-Herttuala S,Jaattela M,Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 178690.
  • 110
    Rosenzweig A. Circulating endothelial progenitors–cells as biomarkers. N Engl J Med 2005; 353: 10557.
  • 111
    Werner N,Kosiol S,Schiegl T,Ahlers P,Walenta K,Link A,Bohm M,Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 9991007.
  • 112
    Kane RC,Farrell AT,Saber H,Tang S,Williams G,Jee JM,Liang C,Booth B,Chidambaram N,Morse D,Sridhara R,Garvey P, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12: 727178.
  • 113
    News in brief. Nat Rev Drug Discov 2005; 4: 44849.
  • 114
    Busby JE,Kim SJ,Yazici S,Nakamura T,Kim JS,He J,Maya M,Wang X,Do KA,Fan D,Fidler IJ. Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells. Prostate 2006; 66: 178898.
  • 115
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 11826.
  • 116
    Sandler A,Gray R,Perry MC,Brahmer J,Schiller JH,Dowlati A,Lilenbaum R,Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 254250.
  • 117
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 5862.
  • 118
    Willett CG,Boucher Y,di Tomaso E,Duda DG,Munn LL,Tong RT,Chung DC,Sahani DV,Kalva SP,Kozin SV,Mino M,Cohen KS, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 1457.
  • 119
    Thiele W,Sleeman JP. Tumor-induced lymphangiogenesis: a target for cancer therapy? J Biotechnol 2006; 124: 22441.
  • 120
    Dadras SS,Lange-Asschenfeldt B,Velasco P,Nguyen L,Vora A,Muzikansky A,Jahnke K,Hauschild A,Hirakawa S,Mihm MC,Detmar M. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005; 18: 123242.
  • 121
    Meyerhardt JA,Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 47687.